Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
2/7/2019Meridian Launches New Range of Lyo-Ready PCR Mixes
CINCINNATI, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to introduce its next-generation lyophilization-ready mixes for one-step RT-qPCR. These master mixes offer new solutions for developing freeze-dried multiplex assays that can simultaneously detect both RNA and DNA viruses.  Lyo-Ready One-Step RT-qPCR and Lyo-Ready One-Step Viral RT-qPCR are glycerol-free for... 
 Printer Friendly Version
1/24/2019Meridian Bioscience Reports First Quarter 2019 Operating Results, Declares Regular First Quarter Cash Dividend, and Provides Updated Fiscal 2019 Guidance
CINCINNATI, Jan. 24, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2018. First Quarter 2019 Highlights: Total revenue decreased 1.5% to $51.5 million, as compared to $52.3 million in the first quarter of fiscal 2018 (1% decrease in constant-currency) Reported operating income of $10.6 million (including $0.6 million of costs associated with litigation), an increase of 31% from the first qu... 
 Printer Friendly Version
1/7/2019Meridian Bioscience Announces Preliminary First Quarter 2019 Revenue; First Quarter 2019 Financial Results Conference Call to be Held on January 24, 2019
CINCINNATI, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, announced that it expects first quarter 2019 revenue to be approximately $51.0 million to $51.5 million compared to $52.3 million in the first quarter of 2018.  The year-over-year decline of approximately 2% is being driven by weakness in the Diagnostics segment.  The Life Science segment is expected to post revenue about in line wit... 
 Printer Friendly Version